approval

MediBeacon Transdermal GFR System Receives FDA Approval to Assess Kidney Function

Transdermal GFR System (TGFR) is a first-in-kind product for point of care assessment of kidney function in patients with normal…

3 months ago

Euro NCAP Boosts Capacity with Approval of DEKRA and TRANSPOLIS Test Centres

Euro NCAP is pleased to announce that DEKRA and TRANSPOLIS have been accredited for Euro NCAP active safety testing, formally…

3 months ago

Euro NCAP Boosts Capacity with Approval of DEKRA and TRANSPOLIS Test Centres

Euro NCAP is pleased to announce that DEKRA and TRANSPOLIS have been accredited for Euro NCAP active safety testing, formally…

3 months ago

HUTCHMED Announces NMPA Full Approval for ORPATHYS(savolitinib) in China for Patients with Locally Advanced or Metastatic MET Exon 14 NSCLC

January 13, 2025 23:00 ET  | Source: HUTCHMED (China) Limited — Indication expands to include treatment-naïve patients — — The 2021…

3 months ago

ZEISS MEL 90 excimer laser receives U.S. FDA approval; completes Corneal Refractive Workflow

The excimer laser complements the ZEISS VISUMAX 800 with ZEISS SMILE pro, extending ZEISS' LVC market leadership with treatment for…

3 months ago

Euro NCAP Boosts Capacity with Approval of DEKRA and TRANSPOLIS Test Centres

Euro NCAP is pleased to announce that DEKRA and TRANSPOLIS have been accredited for Euro NCAP active safety testing, formally…

3 months ago

ZEISS MEL 90 excimer laser receives U.S. FDA approval; completes Corneal Refractive Workflow

The excimer laser complements the ZEISS VISUMAX 800 with ZEISS SMILE pro, extending ZEISS' LVC market leadership with treatment for…

3 months ago

ZEISS MEL 90 excimer laser receives U.S. FDA approval; completes Corneal Refractive Workflow

The excimer laser complements the ZEISS VISUMAX 800 with ZEISS SMILE pro, extending ZEISS' LVC market leadership with treatment for…

3 months ago

SciSparc Announces Renewal of Approval by Israeli Medical Cannabis Agency for its Clinical Trial in Children with Autism Spectrum Disorder

TEL AVIV, Israel, Dec. 31, 2024 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) ("Company" or "SciSparc"), a specialty clinical-stage pharmaceutical…

3 months ago

SciSparc Announces Renewal of Approval by Israeli Medical Cannabis Agency for its Clinical Trial in Children with Autism Spectrum Disorder

TEL AVIV, Israel, Dec. 31, 2024 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) ("Company" or "SciSparc"), a specialty clinical-stage pharmaceutical…

3 months ago
Show more Posts
Show previous Posts